Searched for
SEMAGLUTIDE TABLETS
UK approves Novo weight-loss pill to edge open European marketBritain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatme...- Stocks in news: ITC, Nykaa, Lenskart, Ola Electric, IndusInd BankMarkets saw a volatile session with Nifty trading below the 23,800-24,000 resistance zone, though select heavyweight buying limited downsid...
- Dr Reddy’s launches oral semaglutide in IndiaDr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three ta...
- Dr Reddy's launches oral semaglutide biosimilar Obeda in IndiaDr. Reddy's Laboratories proudly presents Obeda, a groundbreaking oral semaglutide biosimilar for managing Type 2 diabetes in India. This i...
- HAB Pharma merges Signature Phytochemicals, eyes Rs3,000 crore revenue by 2030HAB Pharma and Signature Phytochemicals have merged, creating a consolidated entity with a turnover of Rs600 crore. This strategic move aim...
- Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...
- Novo rebrands diabetes pill as Ozempic to tap blockbuster nameNovo Nordisk is relaunching a diabetes tablet as Ozempic in the United States. This move aims to boost sales by using the strong brand reco...
- Obesity drug market to gain as Indians pop the pill and Chinese bring moreIndia's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, w...
- Dr Reddy's gets nod to roll out generic oral semaglutide drug"The formulation was clinically evaluated in a head-to-head comparative study conducted in India, which established the non-inferiority to ...
- India tightens grip on GLP-1 supply chain amid misuse concerns, expands crackdown on unapproved drugsIndia's drug regulator is increasing checks on weight loss drug sales. This action follows inspections of pharmacies and clinics nationwide...
- Future diabetes care seen leaning towards GLP-1 drugsThe diabetes treatment landscape in India is on the brink of transformation. Innovative GLP-1 medications are set to redefine therapy stand...
- Novo Nordisk gears up for December Ozempic launch in India, sources sayDanish drugmaker Novo Nordisk is set to launch its popular diabetes drug Ozempic in India this month. This move aims to capture a significa...
- Novo Nordisk slashes Wegovy prices in India by up to 37% to boost sluggish sales of weight-loss drugAccording to renowned endocrinologist Dr Shashank Joshi, a steep cut in the prices of Wegovy will help improve access and affordability. “B...
- Weight-loss therapy goes pill-to-shot with higher efficacy, convenienceSales of Novo Nordisk’s oral weight-loss drug Rybelsus have plateaued as Indians increasingly shift to injectable GLP-1 drugs like Eli Lill...
- Weight-loss drug Ozempic to debut in India soonNovo Nordisk will launch Ozempic in India. This injectable drug manages type 2 diabetes and aids weight loss. It enters a competitive marke...
- Weight is over! Pharma companies race to make weight-loss drug semaglutideIndian drugmakers, including Dr. Reddy's and Zydus Lifesciences, are investing heavily in manufacturing capabilities to launch generic vers...
- New oral diabetes + obesity drug's India sales surge 100%India experiences a surge in Rybelsus sales, impacting the anti-obesity market. Semaglutide dominates, reflecting India's obesity challenge...
- Eli Lilly in advanced clinical trials for its weight-loss pillEli Lilly has commenced phase three clinical trials in India for a new oral weight-loss drug called orforglipron. The trials aim to assess ...
- Anti-obesity drug market gaining traction in IndiaAccording to research firm Pharmarack, the market has tripled in two years after witnessing a sluggish growth till 2021. Over the last five...
- Novo Nordisk searches for tablet to replace insulin shotsThe company that reaped nearly 80% of its $16 billion sales from insulin products last year is hopeful for a regulatory approval for its fi...
Load More
